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Abstract
Candida albicans in the immunocompetent host is a benign member of the human microbiota. Though, when host
physiology is disrupted, this commensal-host interaction can degenerate and lead to an opportunistic infection. Relatively
little is known regarding the dynamics of C. albicans colonization and pathogenesis. We developed a C. albicans cell surface
protein microarray to profile the immunoglobulin G response during commensal colonization and candidemia. The
antibody response from the sera of patients with candidemia and our negative control groups indicate that the
immunocompetent host exists in permanent host-pathogen interplay with commensal C. albicans. This report also identifies
cell surface antigens that are specific to different phases (i.e. acute, early and mid convalescence) of candidemia. We
identified a set of thirteen cell surface antigens capable of distinguishing acute candidemia from healthy individuals and
uninfected hospital patients with commensal colonization. Interestingly, a large proportion of these cell surface antigens are
involved in either oxidative stress or drug resistance. In addition, we identified 33 antigenic proteins that are enriched in
convalescent sera of the candidemia patients. Intriguingly, we found within this subset an increase in antigens associated
with heme-associated iron acquisition. These findings have important implications for the mechanisms of C. albicans
colonization as well as the development of systemic infection.
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Introduction
The yeast Candida albicans exists in a dichotomist relationship
with the human host. C. albicans is frequently found as a
commensal organism on the human skin, gastrointestinal (GI)
tract and the vulvovaginal tract [1]. Close to 60% of healthy
individuals carry C. albicans as a commensal in the oral cavity.
Colonic and rectal colonization is even higher, ranging from 45%
to 75% among patient groups. Alterations in the host immunity,
physiology, or normal microflora rather than the acquisition of
novel or hypervirulent factors associated with C. albicans, are
suggested to lead to the development of candidiasis [2]. Both
neutrophils and mucosal integrity of the GI tract, are critical in
preventing hematogenously disseminated candidiasis [3]. The
development of candidemia can begin with the translocation of C.
albicans into the bloodstream from initial commensal GI coloni-
zation or the shedding from developing biofilms on indwelling
catheters [4,5]. Fungal cells that evade the host immune system
can spread to deep organ systems leading to hematogenously
disseminated candidiasis, which has an estimated mortality rate of
40%, even with the use of antifungal drugs [2].
Information on in vivo gene expression would provide insight
into how C. albicans interacts with host cells during the transition
from commensal colonization to an opportunistic pathogen in the
immunocompromised host. However, in vivo transcription profil-
ing of C. albicans during commensal colonization or candidemia is
technically challenging [6]. Instead, several genome-wide tran-
scriptional analyses of C. albicans responses to host cells have been
performed using ex vivo and in vivo infection models. These include
phagocytosis of C. albicans cells by neutrophils [7] and
macrophages [8], exposure to human blood, plasma, and blood
cells [9,10], as well as invasion of perfused pig liver and
reconstituted human epithelium [11,12]. Genes that are associ-
ated with morphological changes, metabolic adaptation, and
oxidative stress are the major responses of C. albicans to host cells
identified in these studies. The changes in gene expression
identified in these in vitro model systems possibly reflect tissue- or
stage-specific expression during an infection in patients. Profiling
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of antibody responses during infection in patients offers an
alternative approach that can overcome technical challenges of in
vivo transcription profiling. An antibody-based approach has been
used to identify C. albicans gene expression during thrush in
individuals with HIV [13].
Currently the isolation of C. albicans from blood cultures is the
standard method for the diagnosis of candidemia. Nevertheless,
blood cultures may only become positive late in infection, and in
one study up to 50% of all autopsy-proven cases of candidemia
were reported as negative in blood cultures [14]. Thus, the ability
to rapidly and easily diagnose candidiasis is urgently needed. An
alternative approach to microbiological confirmation of C.
albicans infection is serological diagnosis. An immunoproteomic
approach using two-dimensional electrophoresis followed by
quantitative Western blotting and mass spectrometry has been
used to profile serologic response to peptides from cell surface
extracts in candidemia [15–17]. A significant proportion of
antigens identified were glycolytic enzymes and heat shock
proteins. An antigenic multiplex consisting of the peptides Bgl2,
Eno1, Pgk1, Met6, Gap1, and Fba1 provides 87% sensitivity and
74% specificity when distinguishing patients with candidemia
from uninfected hospital patients [17]. However, this approach
has several limitations; only the most abundant and soluble
proteins can be resolved on the immunoblot, there is a lack of
reproducibility of cell wall preparations, and most importantly,
there is the inability to account for various stage- and tissue-
specific gene expressions from the cultured cells. These
limitations can be addressed by using a protein microarray to
profile antibody responses [18–21].
To investigate the establishment of the humoral immunity
during commensal sensitization, as well as the adaptive immune
response to candidemia, we have developed a C. albicans cell
surface protein microarray. Our rationale in developing a cell
surface protein microarray is that the cell surface of C. albicans is
the immediate target of the human immune system when C.
albicans cells enter the bloodstream. Cell surface proteins play
important roles in host interaction, and many of them are known
virulence factors. In addition, a recent study showed that there is a
significant expansion of cell wall, secreted and transporter gene
families in pathogenic Candida species in comparison to non-
pathogenic yeasts [22]. In this study, profiling of serological
response on the protein microarray with sera from candidemia
patients, blood-culture negative hospital patients and healthy
individuals lead to the identification of serological signature
specific for acute and convalescent stages of candidemia.
Intriguingly, large proportions of the identified antigens are
involved in oxidative stress, drug resistance and iron acquisition.
Furthermore, strong IgG response to many proteins known to be
induced and/or required for C. albicans invasion of epithelial and
endothelial cells is observed in both candidemia patients and non-
candidemia controls, including all healthy individuals. Our
findings provide new insights into commensal colonization and
pathogenesis of C. albicans, as well as the characterization of
potential serodiagnostic antigens and vaccine candidates.
Results
Sera collection and study population
Hospital patient sera were collected from Shands Hospital at the
University of Florida (UF) (SH-UF) from January 2004 to
December 2006. We collected sera from 21 patients with
candidemia where the etiological agent was C. albicans. The
median time from the date of positive culture to serum collection
was two days. The study population was classified by age, gender,
underlying disease, portal of entry, antifungal received, and
outcome of stay (Table S1). A subset of the candidemia patients
was followed through acute infection (days 0–14) to early
convalescent (week 4) and mid convalescent (week 12) infection.
We also used sera from 12 hospital patients and 50 healthy
individuals who had no evidence of candidiasis as our negative
control groups.
C. albicans cell surface protein microarray construction
and hybridization
C. albicans cell surface proteins were chosen for the protein
microarray because they interact directly with the host and thus
are likely important for colonization and infection, as well as likely
targets for the host immune system. Furthermore, many of their
protein expression levels are regulated in response to extracelluar
signals, such as stress, nutrients, host factors, or changes in
environment. Known antigenic proteins are also included as
controls (Bgl2, Eno1, Pgk1, Gap1, Cdc19, Tkl1, Hsp90, and
members of the Hsp70 family) [15,17]. The collection contains
451 His- and HA-tagged peptides (Table S2) that represent 363
different proteins, since ORFs.3,000 bps were cloned into two or
more segments. All tagged proteins were confirmed individually by
western blot and again on the protein microarray.
We have used the C. albicans cell surface microarray to evaluate
the antibody profile of patients with candidemia against healthy
individuals and uninfected hospital patients to determine relevant
cell surface antigens that correlate with infection. Arrays were
probed with a collection of sera consisting of different stages of
candidemia: acute, early convalescent (approximately 4 weeks
after onset of infection) and mid convalescent (approximately 12
weeks after onset of infection), as well as uninfected hospital
patients and healthy individuals. Figure S1 shows a representative
image of the microarray hybridized with the serum of an acute
candidemia patient. All hybridizations in this study were done
under the same conditions and dilutions with protein microarrays
printed from the same batch. Their serological reactivity is shown
as a heatmap where the antigens are sorted by increasing
normalized global mean intensity, with bright green having the
weakest intensity, red being the strongest, and black in between
(Figure S2). An examination of the IgG response to the entire C.
albicans cell surface protein microarray showed that the mean
global signal intensity was similar among different groups (data not
shown), although antigenic profiles are not identical between
individuals.
Author Summary
Candida albicans has both a benign and pathogenic
association with the human host. Previous to this study,
little was known in regard to how the host humoral system
responds to the commensal colonization of C. albicans, as
well as the development of hematogenously disseminated
candidiasis. We show using a C. albicans cell surface
protein microarray that the immunocompetent host exists
in permanent host-pathogen interplay with commensal C.
albicans, and undergoes stage-specific antibody responses
as the yeast transitions from a benign microbe to an
opportunistic fungal pathogen. Also identified were
serological signatures specific for acute and convalescent
stages of candidemia. Our findings provide new insight in
the characterization of potential serodiagnostic antigens
and vaccine candidates to the opportunistic pathogen C.
albicans.
IgG Profiling on a C. albicans Protein Microarray
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Characterization of an IgG response indicative of
permanent host-pathogen interplay in commensal
colonization
We were interested in determining the most seroprevalent
antibodies in the acute candidemia patients and how their humoral
response compared against the negative control groups. Antigens to
the most seroprevalent antibodies were defined as serodominant
antigens and characterized as having mean antigen reactivity 2-fold
greater than the in vitro transcription/translation reaction mixture
containing no vector. The top-forty serodominant antigens in the
candidemia patients consisted of many previously characterized
antigenic peptides such as Bgl2 [17], Tkl1 [15], Hwp1 [13,23], Eft2
[15], and Cdc24 [13] (Table 1). Also among the top-forty
serodominant antigens were many previously identified virulence-
associated and/or hyphal-regulated proteins (eg. Int1, Hwp1, Als1,
Als3, Als5, Ece1, Hyr1, Cdc24, and Utr2) (Table 1) [24–32].
Interestingly, this serological response of acute candidemia patients
was shared with both uninfected hospital patients and healthy
individuals. The mean signal intensity to the top-forty serodomi-
nant antigens was 8,825 in acute candidemia patients, 8,837 in
uninfected hospital patients, and 10,790 in healthy individuals. A
two-way hierarchical cluster analysis of the top-forty serodominant
antigens shows that the serum specimens of both the positive and
negative candidemia groups were randomly dispersed throughout
the hierarchical tree (Figure 1A). To further confirm that the top-
forty serodominant antigenic signatures are shared among acute
candidemia patients, the uninfected hospital patients and healthy
individuals, principal component analysis (PCA) was used to
generate a three-dimensional projection of the data (Figure 1B,
1C and 1D). The PCA shows that a large proportion of both the
positive and negative acute candidemia sera are clustered together.
These analyses suggest that IgG levels to the top-forty serodominant
antigens are similar in both the negative control groups and acute
candidemia sera. Since many of the top-forty antigens are either
important for or induced during the invasion of epithelial or
endothelial cells [11,33], their expression in healthy people,
inferred from the presence of their antibodies, indicates the
existence of a permanent host-pathogen interplay in immunocom-
petent individuals.
Identification of antigens correlative with the acute-stage
of candidemia
To determine stage-specific biomarkers of acute candidemia,
the normalized serological expression of acute candidemia patients
were compared against the humoral reactivity of the uninfected
hospital patients and healthy individuals. Serodiagnostic antigens
were defined as having an IgG response significantly greater in
acute candidemia patients (days 0–14) as compared to the negative
control groups with Benjamini and Hochberg (BH) adjusted
Cyber-T p-values ,0.05. Thirteen antigens met this requirement
(Table 2). Moreover, among the proteins identified as serodiag-
nostic markers, proteins involved in oxidative stress response
appeared to be enriched over other functional categories. Sln1 and
Nik1 are two out of three histidine kinases on the cell surface
protein microarray and they are both identified as serodiagnostic
antigens. Sln1 and Nik1 are sensors for the high-osmolarity
glycerol (HOG) pathway, a mitogen-activated protein kinase
cascade responsible for osmotic and oxidative stress adaptation in
C. albicans [34,35]. In addition, the expression levels of CDR4,
RAS2, and ALS9 are up-regulated during oxidative stress [35].
Another functional group over-represented among the serodiag-
nostic antigens are transporters associated with drug resistance
(Cdr1, Cdr4, and Yor1) [36].
The 13-serodiagnostic antigens were also evaluated with a two-
way hierarchical cluster analysis on candidemia positive and
negative sera. Interestingly, the sera clustered into two distinct
groups based on their responses to the 13 antigens (Figure 2A).
Cluster I contained 10 candidemia sera and only one uninfected
hospital patient. Cluster II contained all 50 healthy individuals, 11
of the 12 hospital patients, and 8 acute candidemia sera
(Figure 2A). To further confirm that the antigenic signatures
identified during the acute phase of candidemia differed from the
negative control groups, PCA was used to create a three-
dimensional projection of the data (Figure 2B, 2C, and 2D). In
agreement with the two-way hierarchical cluster analysis, two
distinct groups were observed (Figure 2B and 2C). Also, the PCA
of the negative control groups showed individuals are clustered
together with the exception of one outlying uninfected hospital
patient found clustered with the acute candidemia patients
(Figure 2C and 2D). These data provide further support of the
antigenic signature of patients during the acute phase of
candidemia. Multiple linear regression models determined that
the antigenic profiles of acute candidemia patients were not related
to various risk factors (i.e. age, gender, course of treatment,
coexisting disease, and recovery/fatality) (data not shown).
However, this determination is limited by the small sample size
of our study.
Multiple independent serodiagnostic antigens can dramatically
improve the sensitivity and accuracy of serodiagnostic tests [37].
To establish a collection of antigens that could be used as a
multiplex set to accurately distinguish candidemia cases from
controls, we studied the discriminatory power of different sets of
proteins using receiver operating characteristic (ROC) curves.
First, ROC curves were generated for individual serodiagnostic
antigens and the area under the ROC curves (AUC) for each
antigen is listed in Table 2. The top-five cell surface proteins all
have an AUC greater than 0.76, with CDR1 (3) (AUC 0.87, BH
adjusted Cyber-T p-value ,1.04e-7) giving the best single antigen
discrimination (Table 2). The 13th antigen has an AUC of 0.630,
which still exceeds the upper 95% confidence interval for random
expectations for the AUC. To extend the analysis to combinations
of antigens, we used kernel methods and support vector machines
to build linear and nonlinear classifiers. As inputs to the classifier,
we used the highest-ranking AUC antigens in combinations of 2,
5, 10, 11, 12 and 13 proteins and the results were validated with 10
runs of three-fold cross-validation (Figure 2E). Increasing the
antigen number from 2 to 5, and 5 to 10 produced improvements
in the classifier. But as the antigens increased to 13, a reduction in
accuracy was observed. Using the ten most significant diagnostic
antigens (in rank order: Cdr1 (3), Cfl91, Cdr4 (3), Als9 (2), Cdc19,
Nik1 (2), Chs8 (2), Rta4, Sln1 (2), and Trk1 (2)), the classifier
predicts 83% (95% CI, 76–89%) sensitivity, 72% (95% CI, 68–
76%) specificity, and 74% (95% CI, 72–76%) accuracy in
diagnosis of acute phase candidemia from the negative controls
(healthy individuals and uninfected hospital patients) (Table 3).
Identification of antigens correlative with the
convalescent-stage of candidemia
We were next interested in identifying antigens that are
significantly different between the early/mid convalescent
candidemia patients (weeks 4 and 12 of the infection,
respectively) and the negative control groups. The convalescent
patient sera consisted of three patients whose serum was drawn
under all three disease phases (acute phase, early and mid
convalescent phases), 4 patients who had blood drawn at the
acute and early convalescent phases, and 3 patients whose blood
was drawn only at the early convalescent phase. Using BH
IgG Profiling on a C. albicans Protein Microarray
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adjusted Cyber-T p-values ,0.05, we identified 33 antigens, 11
of which are from the 13 diagnostic antigens for the acute phase
of infection (Table 4). Among the identified convalescent
biomarkers were marked expansions in proteins involved in iron
acquisition (Rbt5, Csa1, Flc1, and Cfl91) (Table 4). Cfl91 is a
putative ferric reductase similar to Fre10, which is required for
the release of iron from transferrin and the reduction to ferrous
iron [38]. The protein Flc1 has been identified as having heme
uptake activity [39] whereas, both Rbt5 and Csa1 have been
implicated as receptors of hemoglobin whose function is to
deliver the hemoglobin by endocystosis to the vacuole where iron
is released by acidification [40,41]. The remainders of the
Table 1. The forty most serodominant antigens in acute candidemia patients.
Name Description Mean antigen reactivity (+/2 SEM)
BH adjusted
p-values
Systematic Common Candidemia patients Negative controls
19.4257 (1) Int1 (1) Integrin-like protein 35,380 (11,412–109,691) 32,163 (12,268–84,323) 0.853
19.4421 Cwh41 Glucosidase 32,758 (13,701–78,323) 40,288 (16,253–99,864) 0.642
19.6420 Pga13 Unknown function 27,057 (10,402–70,383) 40,478 (25,960–63,115) 0.116
19.5636 Rbt5 Hemoglobin utilization 19,351 (4,882–76,695) 12,787 (3,956 - 41,338) 0.419
19.1321 Hwp1 Hyphal wall protein 19,136 (4,604–79,530) 15,974 (4,407–57,899) 0.776
19.6763 Slk19 Unknown function 18,546 (6,904–49,823) 15,590 (4,535–53,590) 0.769
19.6481 Yps7 Aspartic-type peptidase 14,170 (4,202–47,787) 15,103 (4,189–54,451) 0.915
19.1816 (2) Als3 (2) Agglutinin-like protein; iron
assimilation
13,292 (5,047–35,009) 16,960 (7,384–38,953) 0.531
19.7298 (1) Chs2 (1) Chitin synthase 12,221 (5,271–28,335) 20,418 (13,475–30,940) 0.0361
19.5788 (1) Eft2 (1) Elongation Factor 2 11,973 (3,530–40,612) 9,139 (3,878–21,538) 0.504
19.3988 Ipf9655 Unknown function 11,642 (5,339–25,386) 12,904 (6,096–27,318) 0.806
19.7565 Gnp3 Glutamine permease 8,919 (2,049–38,826) 6,306 (1,686–23,592) 0.535
19.5632 Phr3 Glucanosyltransferase 8,845 (2,542–30,768) 12,600 (4,498–35,298) 0.436
19.3374 Ece1 Unknown function 8,571 (1,967–37,354) 3,401 (702–16,481) 0.105
19.4565 Bgl2 Glucanosyltransferase 8,437 (4,642–15,334) 5,564 (3,022–10,244) 0.116
19.886 Pan1 Actin cytoskeleton-regulatory
complex
8,368 (2,924–23,953) 14,845 (5,032–43,796) 0.177
19.4257(2) Int1 (2) Integrin-like protein 8,256 (2,986–22,828) 12,856 (4,405–37,517) 0.321
19.5095 (2) Osh2 (2) Oxysterol-binding protein 8,103 (2,696–24,359) 6,953 (1,832–26,385) 0.806
19.5095 (1) Osh2 (1) Oxysterol-binding protein 8,070 (2,178–29,899) 10,254 (3,080–34,142) 0.667
19.4784 (2) Crp1 (2) Copper transporter 7,937 (3,951–15,943) 7,260 (4,836–10,899 0.751
19.2787 Pry1 Unknown function 7,813 (4,172–14,634) 13,674 (9,461–19,764) 0.00451
19.5588 Pga60 Unknown function 7,477 (4,350–12,852) 8,332 (3,111–22,311) 0.808
19.1671 Utr2 Glycosidase 7,466 (4,590–12,144) 8,456 (6,440–11,102) 0.479
19.2003 Hnm1 Choline transporter 7,385 (4,798–11,367) 8,333 (6,454–10,759) 0.470
19.4975 (2) Hyr1 (2) Hyphal wall protein 7,221 (3,177–16,411) 4,665 (2,527–8,610) 0.0814
19.7251 Wsc4 Unknown function 6,906 (3,926–12,150) 9,603 (7,001–13,172) 0.0457
19.3174 (1) Cdc24 (1) GDP-GTP exchange factor 6,888 (3,544–13,387) 10,759 (7,607–15,215) 0.0106
19.575 (2) Hyr3 (2) Unknown function 6,846 (2,378–19,712) 5,695 (2,069–15,676) 0.688
19.932 Dnf2 Phospholipid translocase 6,766 (4,655–9,836) 7,475 (4,596–12,156) 0.688
19.5672 Mep2 Ammonium permease 6,743 (3,949–11,514) 7,885 (3,644–17,059) 0.652
19.4899 (1) Gca1 (1) Glucoamylase 6,640 (2,881–15,302) 9,427 (5,866–15,151) 0.116
19.3225 (1) Cwh43 (1) Unknown function 6,537 (4,850–8,809) 6,671 (4,821–9,231) 0.921
19.1415 Fre10 Ferric reductase 6,528 (4,408–9,667) 9,450 (6,428–13,893) 0.0214
19.5736 (2) Als5 (2) Agglutinin-like protein 6,231 (2,848–13,634) 7,448 (3,933–14,103) 0.556
19.5741 (2) Als1 (2) Agglutinin-like protein 5,795 (2,489–13,495) 10,653 (4,371–25,966) 0.0649
19.3256 (2) Sln1 (2) Histidine kinase; osmosensor 5,561(1,535–20,139) 2,866 (1,695–4,846) 0.00878
19.1357 Fcy21 Purine-cytosine permease 5,445 (3,827–7,748) 5,895 (4,377–7,937) 0.678
19.1690 Tos1 a-agglutinin anchor subunit 5,412 (3,340–8,768) 3,994 (2,535–6,291) 0.116
19.4215 Fet34 Multicopper ferroxidase 5,372 (2,502–11,534) 6,232 (2,745–14,147) 0.689
19.5112 Tkl1 Transketolase 5,337 (2,756–10,335) 7,143 (3,938–12,957) 0.261
doi:10.1371/journal.ppat.1000827.t001
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Figure 1. Prevalence of the serodominant anti-C. albicans cell surface IgGs in the study population. (A) Two-way hierarchical cluster of
the top-forty serodominant antibodies (rows) and serum specimens (columns) from acute candidemia patients (n = 18) and negative controls groups
(hospital patients (n = 12) and healthy individuals (n = 50)). The color scale ranks the antigens with red being the strongest, bright green the weakest,
and black in between. (B, C & D) Principal component analyses of top-forty serodominant anti-C. albicans cell surface IgG antibody expression profiles
between acute candidemia patients and each negative control group (hospital patients and health individuals). Each circle denotes the anti-C.
albicans cell surface antibody profile of a single serum specimen. Samples are color coded as the following acute candidemia patients (red), healthy
individuals (green), and hospital patients (blue).
doi:10.1371/journal.ppat.1000827.g001
IgG Profiling on a C. albicans Protein Microarray
PLoS Pathogens | www.plospathogens.org 5 March 2010 | Volume 6 | Issue 3 | e1000827
identified proteins have roles in cell wall biogenesis, membrane
lipid organization, and drug resistance.
We next evaluated antibody response to the 33 antigens in the
acute, convalescent candidemia patients and the negative control
groups by two-way hierarchical cluster analysis. The individuals in
Cluster II were the same as those identified previously with 13
serodiagnostic antigens (Figure 2A and 3A) with the addition of
one convalescent candidemia patient whose only sera was drawn
during week 4 of the infection. Individuals in Cluster I consisted of
candidemia patients with the exception of the one uninfected
hospital patient from Figure 2A. Three of the candidemia patients’
acute and convalescent profiles were all found in Cluster I,
whereas four candidemia patients’ profiles converted from Cluster
II to I during the convalescence phase of the disease. In addition,
the remaining two-candidemia patients whose only blood draws
were during week 4 also grouped in Cluster I (Figure 3A). This
conversion of the antigenic profile from the negative control
groups (Cluster II) to the antigenic profile consistent with
candidemia (Cluster I), indicates an adaptive immune response
to C. albicans that is different from commensal sensitization. Again,
PCA was used to further confirm that the antigenic signatures
identified during the convalescent phase of candidemia differed
from the negative control groups (Figure 3B, 3C and 3D). ROC
curves were generated to assess the ability to separate the control
and convalescent candidemia. AUC was determined for each of
the 33-serodiagnostic antigens and listed in Table 4 in decreasing
order. The top-five ORFs all have an AUC greater than 0.94. We
then used SVMs to build multiplex classifiers with 2, 5, and 10
antigens with the highest-ranking AUC from Table 4. The results
were validated with 10 runs of three-fold cross-validation
(Figure 3E). Increasing the antigen number from 2 to 5 maintained
the diagnostic accuracy in the classifier and a reduction in
accuracy occurred as the antigens increased to 10 due to over-
fitting. The top-five serodiagnostic antigens are associated with
xenobiotic-transporting activity (Cdr4 and Yor1) [36], phospho-
lipid-transporting activity (Drs23), a putative ferric reductase
(Cfl91), and a mucin-like cell wall protein (Ipf25023) (Table 4).
Using the top-five antigens, the classifier predicts 93% (95% CI,
89–96%) sensitivity, 96% (95% CI, 95–96%) specificity, and 95%
(95% CI, 94–96%) accuracy in the differentiation of early/mid
convalescent phase candidemia from the negative controls (healthy
individuals and uninfected hospital patients) (Table 3).
Having identified 33 antigens that are correlative with
convalescent candidemia in comparison to the negative control
groups, we next wanted to determine the temporal change in IgG
response to these 33 antigens during the transition from acute
infection (AI), to early convalescent (EC), and mid convalescent
(MC). A two-way hierarchical cluster analyses was performed on
differential IgG responses to the 33 antigens in 3 patients with AI,
EC and MC sera, and 4 patients with only AI and EC sera (Figure
S3). A one tailed t-test was carried out to look for differences where
the EC antigen intensity is significantly greater than the AI antigen
intensity, possibly indicating the selection of a protective antibody
response. We observed a significant increase in the IgG response
from AI to EC in the following antigens, which are ranked
according to their p-values: Apc5 (2) (1.12E-03), Drs23 (3) (1.23E-
03), Vps62 (1.57E-03), Rad50 (1.83E-03), Ssu1 (3.17E-03), Yor1
(3) (5.33E-03), Ipf885 (5.33E-03), Pga4 (5.88E-03), Cdr4 (3)
(7.22E-03), Cfl91 (2) (0.0231), Cyr1 (2) (0.0274), Ipf25023 (2)
(0.0330), Gsl2 (2) (0.0374), Chs1 (2) (0.0393), and Snq2 (3)
(0.0486). The identified antigens could potentially be efficacious
vaccine candidates due to the fact that the IgG response is being
positively selected over the course of infection.
Discussion
In this study, we have developed a C. albicans cell surface protein
microarray and profiled host humoral responses during con-
mmensal colonization and during the progression of candidemia.
Thirteen novel serodiagnostic antigens were identified for
differentiating acute candidemia from commensal sensitization
and 33 antigens were found to discriminate convalescent
candidemia from non-candidemia controls. The sensitivity and
specificity for the identification of acute candidemia determined by
the top 10 antigens from the set of 13 serodiagnostic markers are
comparable to that obtained using the method of 2D-PAGE and
Table 2. Antigenic biomarkers of the acute candidemia patients.
Name Description Mean antigen reactivity (+/- SEM)
BH adjusted
p-value AUC
Systematic Common Candidemia patients Negative controls
19.6000 (3) Cdr1 (3) Drug transporter 2,842 (1,295–6,234) 837 (440–1,593) 1.04E-07 0.873
19.1844 Cfl91 Ferric reductase 3,522 (778–15,943) 752 (329–1,719) 1.47E-06 0.792
19.5079 (3) Cdr4 (3) Drug transporter 4,433 (2,104–9,341) 2,089 (1,285–3,394) 1.07E-04 0.777
19.5742 (2) Als9 (2) Agglutinin-like protein 4,233 (2,167–8,267) 2,025 (1,037–3,956) 1.96E-03 0.786
19.3575 Cdc19 Pyruvate kinase 3,235 (1,364–7,673) 1,704 (960–3,024) 6.10E-03 0.755
19.5181 (2) Nik1 (2) Osmosensor 2,420 (975 – 6,008) 1,198 (605–2,372) 6.51E-03 0.722
19.5384 (2) Chs8 (2) Chitin synthase 2,306 (984–5,402) 1,267 (739–2,170) 6.69E-03 0.750
19.6595 Rta4 Phospholipid transporter 3,011 (1,802–5,030) 1,506 (690–3,285) 6.94E-03 0.764
19.3256 (2) Sln1 (2) Osmosensor 5,561 (1,535–20,139) 2,866 (1,695–4,846) 8.78E-03 0.630
19.600 (2) Trk1 (2) Potassium transporter 2,780 (1,483–5,211) 1,652 (890–3,066) 0.0214 0.784
19.1783 (3) Yor1 (3) Drug transporter 2,566 (1,024–6,427) 1,593 (989–2,565) 0.0269 0.651
19.6926 Csc25 Guanyl-nucleotide
exchange factor
2,507 (1,710–3,675) 1,563 (834–2,930) 0.0362 0.735
19.5902 Ras2 RAS signal transduction 3,005 (1,872–4,824) 2,032 (1,234–3,348) 0.0417 0.704
doi:10.1371/journal.ppat.1000827.t002
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Figure 2. Discrimination of acute candidemia patients from the study population. (A) Two-way hierarchical cluster analyses of the 13
differentially expressed anti-C. albicans cell surface antibodies in acute candidemia sera. The heatmap is organized with antigens, in rows, and acute
candidemia patients (n = 18) and negative controls groups (hospital patients (n = 12) and healthy individuals (n = 50)) in columns. The colorized scale
ranks the antigens with red being the strongest, bright green the weakest, and black in between. (B, C & D) Principal component analyses of serum
anti-C. albicans cell surface IgG antibody expression profiles that discriminate between candidemia patients and each negative control group
(hospital patients and health individuals). Each circle denotes the anti-C. albicans cell surface antibody profile of a single serum specimen. Samples are
color coded as the following acute candidemia patients (red), healthy individuals (green), and hospital patients (blue). (E) The graph shows the ROC
curves generated using different sets of acute serodiagnositc antigens.
doi:10.1371/journal.ppat.1000827.g002
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immunoblots [17]. When using the top 5 antigens from the set of
33, both sensitivity and specificity are dramatically improved for
convalescent candidemia. Pitarch et al. reported that the anti-
Bgl2p IgG antibody levels mainly define the proteomic signature
for candidemia patients [17]. In this study, Bgl2 is on the list of 33
diagnostic antigens from convalescent sera. Although it is classified
as a serodominant antigen by acute candidemia sera, the BH-
adjusted p-value of Bgl2 (0.116) is just above cutoff (0.05) to be
considered as diagnostic by our definition, and the mean anti-Bgl2
antibodies in acute candidemia is higher than the mean in non-
candidemia controls. Bgl2 is a glycoprotein and the glycan
moieties on other b-1,3-glucanosyltransferases seem to contribute
to antigenicity. Since our Bgl2 is expressed in vitro without any
glycosylation, its antigenicity is likely different from the Bgl2
produced by C. albicans used in the 2D-PAGE immunoblots. The
previously identified immunogenic heat shock protein 90 (Hsp90)
is also one of 33 biomarkers for convalescent candidemia identified
from this study. Hsp90 has been shown to elicit a protective
humoral response [42,43] and its antibodies are known to
associate with patients that recover from candidiasis. The use of
protein microarray technology allowed us to identify new
diagnostic antigens that were missed by previous studies. The
use of 2-D PAGE to accurately identify and separate clinical
markers of candidemia from commensal sensitization is limited by
the range in protein abundance and various properties associated
with peptides such as their mass, isoelectric point, hydrophobicity,
and post-translational modification, as well as the semi-quantita-
tive nature of a Western [18]. Using a C. albicans cell surface
protein microarray helped us overcome many of the technical
difficulties found with traditional proteomics, since the expression
level of recombinant-derived proteins vary by only a single log and
the use of fluorescent-labeled antibodies allows for greater
linearity, precision, and sensitivity in the quantitative measure-
ment of the humoral response to C. albicans. One of the most
beneficial aspects in the use of the protein microarray assay is its
ability to detect significant differences in the IgG response that
under traditional immunoblot conditions would be below the
detectable threshold. However, a potential limitation to our study
is that the microarray is based on recombinant peptides. Because
of the cell free nature of our in vitro translated peptides, potential
epitopes may have been lost due to miss folding and a lack of
glycosylation, both of which may affect the conformational
structure of the native protein. On the other hand, the removal
of posttranslational modifications, such as glycosylation, from the
peptides may have revealed hidden peptide epitopes only seen
during a strong host immune response. A large collection of
peptide epitopes may increase the specificity in diagnosis of
infection. In support of this, our study has identified many new
clinical biomarkers that are associated with differing states of
interactions with the host as well as the characterization of
potential new targets for therapeutics and vaccine candidates. To
our knowledge, this is the first study using a protein microarray to
analyze the serological response to an organism that is capable of
existing as both commensal flora and an opportunistic pathogen in
the human population.
Commensal colonization of C. albicans is common in humans
and attenuated host immunity is a perquisite for the transition
from commensal colonization to infection. Historically, it was
believed that C. albicans switched from a commensal to a pathogen
using distinct pathogen-associated genetic programs when the host
immune status was altered. An intriguing review challenges this
notion, Hube postulates that C. albicans exists in a permanent host-
pathogen interplay where overgrowth and invasion is only
observed under immunocompromising conditions[44]. The review
puts forth two-models of a permanent infection strategy: (1)
constitutive gene expression where attenuated immunity induces
little or no change in the pathogenic profile of C. albicans or (2) a
variable transcriptional profile where C. albicans expression is
dependent on the stage- and tissue-specific interactions with the
host. Our study indicates the existence of permanent host-
pathogen interplay with variable gene expression over the course
of infection. The serological response to the entire C. albicans cell
surface protein microarray detected considerable homogeneity as
well as differences in the patterns of antigens recognized among
patients and healthy individuals. The majority of healthy
individuals and uninfected hospital patients have moderate to
strong IgG responses to many C. albicans cell surface proteins that
have long been associated with virulence or hyphal-regulation (a
hallmark of virulence in itself). In agreement with our protein
microarray data, Naglik et al. observed similar levels of IgG titers to
the hyphal wall protein Hwp1 in patients with oral candidiasis and
asymptomatic mucosal infections as well as healthy culture-
negative controls [23]. These serodominant cross-reactive antigens
include adhesins such as Als1, Als3, Als5, Hwp1 and Int1 and
hyphal-regulated genes such as Als3, Hwp1, Ece1, Hyr1, and
Cdc24. Both functional groups are known to be important for
invasion and virulence [45]. Among the identified serodominant
antigens are many previously characterized immunogenic peptides
such as Bgl2 [17], Tkl1 [15], Hwp1 [13,23], Eft2 [15], and Cdc24
[13]. Intriguingly, the average signal intensities to the top-forty
serodominant antigens are higher in the healthy individuals than
the uninfected hospital patients and acute candidiasis patients
(10,380 vs. 8,837 and 8,825, respectively). It is interesting to
speculate whether the healthy individuals’ IgG response limits
colonization and overgrowth since many of the serodominant
antigens are against adhesins. In particular is the strong humoral
response to the integrin-like protein, Int1, which may play dual
roles in limiting both intestinal colonization of the cecum and
systemic invasion of deep tissue organs [46,47]. Another
interesting serodominant antibody response is to the protein
Ece1, which has been shown to promote adhesion and is
important for GI colonization[48]. ECE1 transcription is highly
expressed during GI colonization and invasion of host tissue
[33,48]. However, one can not discount that the high IgG titer of
colonized individuals may be due to a previous superficial
infections such candidal vaginitis [49,50].
The microenvironmental conditions during commensal coloni-
zation of the host may also play a role in the induction of the IgG
response to certain cell surface proteins. Previous studies have
Table 3. Test operating characteristics of the clinical
biomarkers.
Percentage (CI 95%)
C. albicans clinical
biomarkers Sensitivity Specificity Accuracy
Acute phase1 83 (76–89) 72 (68–76) 74 (72–76)
Convalescent phase2 93 (89–96) 96 (95–96) 95 (94–96)
1On the basis of two-way hierarchical cluster results of the top ten differentially
expressed anti-C. albicans cell surface IgG antibodies from acute phase (days 0-
14) of candidemia patients and negative control groups (i.e. healthy individuals
and hospital patients).
2On the basis of two-way hierarchical cluster results of the top five differentially
expressed anti-C. albicans cell surface IgG antibodies from early (week 4) and
mid (week 12) convalescent phases of candidemia patients and negative
control groups (i.e. healthy individuals and hospital patients).
doi:10.1371/journal.ppat.1000827.t003
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evaluated characteristics common to the GI and/or vulvovaginal
tract such as blood, hypoxia, iron restriction and weak acid as
modifiers of gene expression [9,51–53]. Intriguingly, the expres-
sions of these genes share common features to the identified
serodominant antibodies. Interestingly, genes transcriptionally up-
regulated in blood (Als1, Als3, Hwp1, Ece1, Hyr1, and Bgl2) were
serodominant and cross-reactive with both positive and negative
candidiasis individuals, as were genes up-regulated under hypoxic
conditions (Als1, Als3, Hwp1, Rbt5, Utr2, and Tos1), iron
restriction (Int1, Rbt5, and Fet35), and weak acid (Crp1, Fet35,
and Ipf9655) (Table 1). Furthermore, some of the serodominant
antigens (i.e. Als3, Ece1, Hwp1, and Rbt5) have been shown to be
induced during the invasion of epithelial or endothelial cells
[11,33]. Therefore, the expression of the serodominant antigens in
healthy individuals indicates the existence of permanent host-
pathogen interplay during commensal colonization. In addition,
the presence of serodominant IgGs in all 50 healthy individuals
suggests that commensal colonization is much more prevalent than
previously reported.
One of the most challenging tasks in characterizing serodiag-
nostic antigens from C. albicans is the identification of discriminat-
ing peptides that can differentiate between commensal coloniza-
tion and candidemia with high sensitivity and specificity. By
profiling antibody response from patients with varying stages of
candidemia against healthy individuals and candidemia-negative
hospital patients, we have identified 13 diagnostic antigens for
Table 4. Antigenic biomarkers of the early and mid convalescent candidemia patients.
Name Description Mean antigen reactivity (+/- SEM)
BH adjusted
p-value AUC
Systematic Common Candidemia patients Negative controls
19.1844 Cfl91 Ferric reductase 10,699 (4,436–25,802) 752 (329–1,719) 0 0.969
19.323 (2) Drs23 (2) Phospholipid translocase 3,249 (1,812–5,826) 707 (439–1,137) 4.21E-14 0.960
19.5079 (3) Cdr4 (3) Drug transporter 9,831 (5,588–17,295) 2,089 (1,285–3,394) 2.28E-13 0.957
19.2296 (2) Ipf25023 (2) Unknown function 3,128 (1,446–6,763) 461 (234–908) 3.46E-13 0.945
19.1783 (3) Yor1 (3) Drug transporter 6,719 (3,759–12,009) 1,593 (989–2,565) 6.91E-13 0.970
19.6000 (3) Cdr1 (3) Drug transporter 3,635 (2,139–6,178) 837 (440–1,593) 1.00E-09 0.964
19.7414 (2) Als6 (2) Agglutinin-like protein 2,868 (1,176–6,990) 883 (569–1,372) 4.56E-09 0.917
19.1800 Vps62 Unknown function 19,259 (10,436–35,543) 5,032 (2,139–11,841) 1.33E-05 0.896
19.5759 (3) Snq2 (3) Drug transporter 2,580 (1,740–3,825) 1,313 (918–1,877) 1.82E-05 0.896
19.5742 (2) Als9 (2) Agglutinin-like protein 5,504 (3,654–8,290) 2,025 (1,037–3,956) 3.14E-05 0.913
19.5636 Rbt5 Hemoglobin utilization 67,414 (30,441–149,296) 12,787 (3,956–41,338) 5.45E-05 0.878
19.600 (2) Trk1 (2) Potassium transporter 4,189 (2,131–8,233) 1,652 (890–3,066) 1.07E-04 0.922
19.4565 Bgl2 Glucanosyltransferase 13,462 (7,309–24,793) 5,564 (3,022–10,244) 2.53E-04 0.866
19.5181 (2) Nik1 (2) Osmosensor 3,090 (1,075–8,878) 1,198 (605–2,372) 4.58E-04 0.945
19.6595 Rta4 Phospholipid transporter 3,847 (2,330–6,354) 1,506 (690–3,285) 4.99E-04 0.837
19.5384 (2) Chs8 (2) Chitin synthase 2,551 (1,650–3,942) 1,267 (739–2,170) 6.32E-04 0.841
19.7214 Ipf885 Glucosidase 2,948 (1,260–6,898) 1,308 (675–2,534) 1.58E-03 0.764
19.4015 Cag1 a-subunit of heterotrimeric
G protein
7,808 (3,381–18,032) 4,380 (3,029–6,334) 1.58E-03 0.761
19.2946 Hnm4 Choline permease 3,001 (1,378–6,537) 1,251 (580–2,697) 1.76E-03 0.775
19.6861 (2) Apc5 (2) Subunit of Anaphase-
Promoting Complex
4,529 (2,365–8,674) 2,054 (1,022–4,129) 2.00E-03 0.793
19.3256 (2) Sln1 (2) Osmosensor 6,043 (1,635–22,332) 2,866 (1,695–4,846) 2.99E-03 0.639
19.6515 Hsp90 Heat shock protein 6,188 (1,263–30,307) 2,652 (1,481–4,748) 3.06E-03 0.620
19.3575 Cdc19 Pyruvate kinase 3,613 (1,033–12,639) 1,704 (960–3,024) 3.44E-03 0.706
19.7114 (2) Csa1 (2) Hemoglobin utilization 9,329 (4,016–21,671) 2,713 (792–9,293) 3.71E-03 0.798
19.3269 (2) Gsl2 (2) Glucan synthase 3,898 (2,725–5,575) 2,418 (1,561–3,746) 6.80E-03 0.806
19.4035 Pga4 Glucanosyltransferase 3,909 (2,496–6,124) 2,326 (1,297–4,170) 0.0203 0.774
19.2501 (2) Flc1 (2) Heme transporter 2,565 (1,564–4,208) 1,620 (1,004–2,615) 0.0220 0.774
19.7298 (2) Chs1 (2) Chitin synthase 2,504 (1,660–4,208) 1,529 (855–2,733) 0.0346 0.752
19.4940 Ipf22247 Histidine permease 4,801(2,852–8,081) 3,096 (1,887–5,078) 0.0391 0.730
19.2222 Yck22 Unknown function 4,387 (3,338–5,767) 2,913 (1,795–4,728) 0.0391 0.795
19.7313 Ssu1 Sulfite transporter 3,753 (2,853–4,936) 2,503 (1,533–4,085) 0.0405 0.775
19.1648 (1) Rad50 (1) DNA double strand
break repair
6,226 (2,722–14,237) 3,323 (1,572–7,024) 0.0405 0.715
19.5148 (2) Cyr1 (2) Adenylyl cyclase 3,042 (2,240–4,130) 1,880 (1,002–3,526) 0.0478 0.747
doi:10.1371/journal.ppat.1000827.t004
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acute phase of candidemia and 33 for the early/mid convalescent
candidemia. The serologic signature in candidemia patients likely
reflects an alteration in the level of those proteins due to a change
either in transcription and/or protein stability. Stage- and tissue-
specific gene expression during the course of systemic infection is
expected as C. albicans cells transition through differing microen-
vironments of the host. Among the 13 diagnostic antigens for acute
candidemia, three are associated with drug resistance (Cdr1, Cdr4,
and Yor1) [36]. The exposure to antifungal drugs in patients
undergoing acute candidemia may have acted as an additional
environmental stress that stimulates the expression of these
antifungal drug transporters [54]. Intriguingly, two out of the 13
biomarkers are the osmosensors Sln1 and Nik1 for the HOG
pathway that is responsible for osmotic and oxidative stress
adaptation in C. albicans [34,35]. The host-pathogen interaction
commonly associated with oxidative stress is typically seen during
phagocytosis by neutrophils, the initiating immune response to C.
albicans overgrowth and infection. Furthermore, a study of global
transcriptional responses to oxidative stress observed an increase in
the transcriptional expression of CDR4 (4.1-fold), RAS2 (2.5-fold)
and ALS9 (1.5-fold) [35]. Taken together, our data indicates a
strong correlation between the IgG response to oxidative stress-
related cell surface proteins and the initial cell-mediated immune
response during acute candidemia. In further agreement, previous
studies have shown that oxidative stress functions are primarily
induced when C. albicans is initially exposed to human blood or
following phagocytosis by neutrophils and granulocytes
[7,9,10,55]. The 33 convalescent diagnostic antigens include
proteins involved in iron acquisition, cell wall biogenesis,
membrane lipid organization, and drug resistance. Of particular
interest is the dramatic increase in antibodies to proteins for iron
acquisition (Cfl91, ferric reductase; Rbt5 and Csa1, hemoglobin
receptors; and Flc1, heme uptake). Iron is an essential nutrient for
C. albicans. Circulating iron in serum is bound to transferrin and
ferric reductases are required in the acquisition of iron from
transferrin. Interestingly, Cfl91 is found as a biomarker for both
acute and convalescent candidemia patients. Of particular interest
is the increase antibody response to hemoglobin and heme-related
proteins as these molecules are normally sequestered in erythro-
cytes [56]. The proteins Rbt5, Csa1 and Flc1 are required for iron
acquisition from hemoglobin or heme [39,40] and are diagnostic
antigens only for convalescent candidemia. Thus, it is interesting
to speculate whether free hemoglobin becomes a by-product of
lysed erythrocytes after post-operative surgery or other invasive
clinical procedures. Nevertheless, the data from this study should
provide critical information for the development of diagnostic
antigenic profiles for patients at risk for candidemia and for the
assessment of progression of hematogenously disseminated candi-
diasis. Future studies will need to be done to determine whether
serological differences exist between superficial and systemic
infections, as well as commensal sensitization.
The development of the antigenic profiles over the course of
candidiasis (acute infection, early convalescence, and mid
convalescence) may also provide insight into a protective humoral
response against C. albicans. Even though previous sensitization to
commensal colonization does not limit mortality or even morbidity
in patients, experimental studies have identified protective
antibodies against hematogenously disseminated candidiasis, such
as heat shock protein 90 (Hsp90) or b-mannan [57–60]. Future
studies will need to address whether the serodiagnostic antigens
identified in this study could provide protection from hematoge-
nously disseminated candidiasis. Of particular interest are the
convalescent serodiagnostic antigens where the EC antigen
intensity is significantly greater than the AI antigen intensity,
which may possibly indicate the selection of a protective antibody
response.
Materials and Methods
Ethics statement
Human sera from candidemia patients and hospitalized patients
were collected from SH-UF under protocols approved and created
by the UF Institutional Review Board. Sera from healthy
individuals were obtained from volunteers at the General Clinical
Research Center at the University of California, Irvine. Written,
informed consent was obtained from participants.
Collection of candidemia and control sera
Candidemia was defined as the recovery of C. albicans from
blood cultures. Sera from candidemia patients and hospitalized
patients (no clinical or microbiological evidence of candidemia)
were collected from SH-UF as previously published [61]. Briefly,
patients at SH-UF were identified on the day blood cultures were
positive for C. albicans. The Infectious Diseases Consultation
Service at SH-UF identified controls. Sera were collected and
stored at 270uC in the repository at the UF Mycology Research
Unit. For patients with candidemia, sera were obtained from the
earliest possible date on or after the date that the first positive
cultures were drawn. In all cases, this was within 7 days of the first
positive culture (acute-phase sera). For ten patients with candide-
mia, sera were also recovered 4 to 12 weeks after the date on
which the first positive cultures were drawn (convalescent-phase
sera).
Microarray construction and antibody profiling
Cell surface proteins were selected from the Candida Genome
Database (CGD) using keywords such as ‘‘cell surface’’, ‘‘plasma
membrane’’, and ‘‘cell wall’’. The CGD annotation of cell surface
proteins is based on published experiments [32,62–66], function-
based prediction of cellular localization, and sequence prediction.
Known antigenic proteins are also included as controls (Bgl2,
Eno1, Pgk1, Gap1, Cdc19, Tkl1, Hsp90, and members of the
Hsp70 family) [15,17]. Coding regions of the genes were PCR
amplified from the clinical isolate SC5314 of C. albicans with
primers listed in Table S2, and cloned into a pXT7 expression
vector with a HA-tag at the N-terminus and His-tag at the C-
terminus by homologous recombination in E. coli as described
[67]. Protein expression was carried out using an E. coli based cell-
Figure 3. Discrimination of convalescent candidemia patients from the study population. (A) Two-way hierarchical cluster analyses of the
33 differentially expressed anti-C. albicans cell surface antibodies from early/mid convalescent candidemia sera. The heatmap is organized with
antigens, in rows, and acute candidemia patients (n = 18), early and mid convalescent patients (n = 10) and negative control groups (hospital patients
(n = 12) and healthy individuals (n = 50)) in columns. The colorized scale ranks the antigens with red being the strongest, bright green the weakest,
and black in between. (B, C & D) Principal component analyses of serum anti-C. albicans cell surface IgG antibody expression profiles that discriminate
between convalescent candidemia patients and each negative control group (hospital patients and health individuals). Each circle denotes the anti-C.
albicans cell surface antibody profile of asingle serum specimen. Samples are color coded as the following acute candidemia patients (red),
convalescent candidemia patients (brown), healthy individuals (green), and hospital patients (blue). (E) The graph shows the ROC curves generated
using different sets of serodiagnostic antigens.
doi:10.1371/journal.ppat.1000827.g003
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free in vitro transcription/translation system (RTS 100 E. coli HY
kit, Roche). The protein microarray was made by printing the
peptides onto nitrocellulose-coated FAST glass slides (Schleicher &
Schuell) using the OmniGrid 100 (GeneMachines) in the UCI
Microarray Facility. Each peptide was printed in duplicate and
showed homogenous spot morphology as well as low background.
Internal controls consisting of buffer alone and a reaction mixture
with no DNA were also printed onto the FAST slides. After the
addition of the plasma samples the microarray was incubated with
a biotin-conjugated donkey anti-human IgG Fcc fragment specific
secondary antibody (Jackson Immunoresearch). The secondary
antibody was then removed and the microarray was incubated
with Streptavidin: SureLight H P-3 (Columbia Biosciences). Details
concerning microarray construction and controls, antibody
profiling, data normalization, as well as the reproducibility and
validity of the microarray are given in the Text S1.
Statistical analysis
All analysis was performed using the R statistical environment
(http://www.r-project.org). It has been noted in the literature that
data derived from microarray platforms is heteroskedatic [68–70].
This mean-variance dependence has been observed in the arrays
presented in this manuscript [71,72]. In order to stabilize the
variance, the vsn method [73] implemented as part of the
Bioconductor suite (www.bioconductor.org) was applied to the
quantified array intensities. In addition to removing heteroskeda-
city, this procedure corrects for non-specific noise effects by
finding maximum likelihood shifting and scaling parameters for
each array such that the variances of a large number (default
setting used: 85%) of the spots on the array are minimized. In
other words, the method assumes that variance in binding for the
vast majority of the proteins on the array are due to noise rather
than true differential immunological response. In essence, 85% of
the spots on the array are used as controls for sample-by-sample
normalization. This calibration method has been shown to be
effective on a number of platforms [74–76]. A simple ranking
normalization where all of the proteins are ordered for each
sample by binding intensity and assigning the integer rank was
performed as well with similar results (results not shown). Finally,
VSN normalized data is retransformed with the ‘sinh’ function to
allow visualization and discussion at an approximate raw scale.
Diagnostic biomarkers between groups were determined using a
Bayes regularized t-test adapted from Cyber-T for protein arrays
[69,77]. To account for multiple testing conditions, the Benjamini
and Hochberg (BH) method was used to control the false discovery
rate [78]. Statistical analyses were performed with R 2.0 (www.r-
project.org) and STATA (version 10.0, StataCorp). Multiple
antigen classifiers were constructed using linear and non-linear
Support Vector Machines (SVMs) using the ‘‘e1071’’ R package.
To prevent overfitting and show the generalization of the
classification method, 10 repeats of three-fold cross-validation
were performed. In this methodology, the data is split into 3 class-
stratified subsets. For each subset, a classifier is trained using the
remaining two-thirds of the data. The classifier is then evaluated
on the one-third of the data not used for training. This process is
repeated for each split and for 10 different splits, yielding 30
evaluation measures. The ROCR package was used to construct
receiver-operating-characteristic curves and perform sensitivity
and specificity analyses. Blast2Go (www.blast2go.org) was used for
gene ontology annotation and enrichment analysis. To confirm
that the identified antigens were accurate, their vectors were
resequenced. The Tables S3 and S4 list the statistical data of acute
and convalescent candidemia patients, respectively.
Accession numbers
Detailed information for the genes/proteins from this study can
be found at the Candida Genome Database http://www.
candidagenome.org. The gene names and ORF numbers are
listed here: INT1 (19.4257), CWH41 (19.4421), PGA13 (19.6420),
RBT5 (19.5636), HWP1 (19.1321), SLK19 (19.6763), YPS7
(19.6481), ALS3 (19.1816), CHS2 (19.7298), EFT2 (19.5788),
IPF9655 (19.3988), GNP3 (19.7565), PHR3 (19.5632), ECE1
(19.3374), BGL2 (19.4565), PAN1 (19.19.886), OSH2 (19.5095),
CRP1 (19.4784), PRY1 (19.2787), PGA60 (19.5588), UTR2
(19.1671), HNM1 (19.2003), HYR1 (19.4975), WSC4 (19.7251),
CDC24 (19.3174), HYR3 (19.575), DNF2 (19.932), MEP2
(19.5672), GCA1 (19.4899), CWH43 (19.3225), FRE10 (19.1415),
ALS5 (19.5736), ALS1 (19.5741), SLN1 (19.3256), FCY21 (19.1357),
TOS1 (19.1690), FET34 (19.4215), TKL1 (19.5112), CDR1
(19.6000), CFL91 (19.1844), CDR4 (19.5079), ALS9 (19.5742),
CDC19 (19.3575), NIK1 (19.5181), CHS8 (19.5384), RTA4
(19.6595), TRK1 (19.600), YOR1 (19.1783), CSC25 (19.6926),
RAS2 (19.5902), DRS23 (19.323), IPF25023 (19.2296), ALS6
(19.7414), VPS62 (19.1800), SNQ2 (19.5759), IPF885 (19.7214),
CAG1 (19.4015), HNM4 (19.2946), APC5 (19.6861), HSP90
(19.6515), CSA1 (19.7114), GSL2 (19.3269), PGA4 (19.4035),
FLC1 (19.2501), CHS1 (19.7298), IPF22247 (19.4940), YCK22
(19.2222), SSU1 (19.7313), RAD50 (19.1648), and CYR1 (19.5148).
Supporting Information
Text S1 Supplemental Experimental Procedures and Supple-
mental References
Found at: doi:10.1371/journal.ppat.1000827.s001 (0.08 MB
DOC)
Figure S1 C. albicans cell surface protein microarray. Represen-
tative image of the cell surface protein microarray of C. albicans
hybridized with the sera of an acute candidemia patient. The array
consisted of sixteen subsets. Each of the C. albicans cell surface
peptides were printed in duplicate. The yellow box indicates a
duplicated print of buffer alone and the red box shows a duplicate
print of reaction mixture with no DNA.
Found at: doi:10.1371/journal.ppat.1000827.s002 (0.13 MB PDF)
Figure S2 Global expression profile of C. albicans cell surface
antigens. Heatmap of the entire C. albicans cell surface protein
microarray probed with a collection of acute candidemia patients
(n = 18), early and mid convalescent candidemia patients (n = 10),
uninfected hospital patients (n = 12) and healthy individuals
(n = 50). The antigens are in columns and are sorted by
normalized mean intensity. The colorized scale ranks the antigens
with red being the strongest, bright green the weakest, and black in
between.
Found at: doi:10.1371/journal.ppat.1000827.s003 (0.22 MB PDF)
Figure S3 Development of the antigenic profile overtime in
candidiasis patients. Two-way hierarchical cluster analyses of
differential IgG response to the 33 convalescent serodiagnostic
antigens (rows) and serum specimens (columns) from candidemia
patients. The patients are ordered from left to right starting with
the acute infection (AI) phase, early convalescent (EC), and mid
convalescent (MC). The colorized scale ranks the antigens with red
being the strongest, bright green the weakest, and black in
between. Cell surface proteins that showed a significant increase in
IgG response from AI to EC are labeled red (p-value #0.05).
Found at: doi:10.1371/journal.ppat.1000827.s004 (0.17 MB PDF)
Table S1 Study population characteristics
Found at: doi:10.1371/journal.ppat.1000827.s005 (0.03 MB PDF)
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Table S2 List of proteins and primer sequences on microarray
Found at: doi:10.1371/journal.ppat.1000827.s006 (0.22 MB XLS)
Table S3 Statistical data of acute candidemia patients
Found at: doi:10.1371/journal.ppat.1000827.s007 (0.24 MB XLS)
Table S4 Statistical data of convalescent candidemia patients
Found at: doi:10.1371/journal.ppat.1000827.s008 (0.28 MB XLS)
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